Join to View Full Profile
900 W 38th StSte 110Austin, TX 78705
Phone+1 512-505-5500
Fax+1 512-334-2702
Dr. Rodriguez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicinePost-Doctoral Fellowship, 2007 - 2009- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
- Baylor College of MedicineResidency, Internal Medicine, 2002 - 2005
Universidad Central del Caribe School of MedicineClass of 2002
Certifications & Licensure
TX State Medical License 2004 - 2026
Clinical Trials
- S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).Laura M Spring, Lauren Scarpetti, Arielle J Medford, Andrzej Niemierko, Amy Comander
NPJ Breast Cancer. 2025-01-07 - Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.Tomoko Akaike, Manisha Thakuria, Ann W Silk, Daniel S Hippe, Song Youn Park
Journal of Clinical Oncology. 2024-09-10 - 6 citationsSerial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.Jacqueline A Shaw, Karen Page, Evie Wren, Elza C de Bruin, Ekaterina Kalashnikova
JCO Precision Oncology. 2024-04-01
Press Mentions
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast CancerMarch 10th, 2025- Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer SymposiumNovember 25th, 2024
- Catching Cancer Red-HandedDecember 1st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
